Golimumab in adolescents with Crohn's disease refractory to previous tumour necrosis factor antibody

AIM: Anti‐tumour necrosis factor (TNF)‐α drugs are effective treatments for the management of moderate/severe Crohn's disease (CD), but treatment failure is common. In the treatment of paediatric CD, there are no data about the use of a third introduced subcutaneous TNF antibody golimumab. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Pichler, Judith, Memaran, Nima, Huber, Wolf Dietrich, Aufricht, Christoph, Bidmon‐Fliegenschnee, Bettina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Regular Articles & Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891654/
https://www.ncbi.nlm.nih.gov/pubmed/32781480
http://dx.doi.org/10.1111/apa.15522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891654/
https://www.ncbi.nlm.nih.gov/pubmed/32781480
http://dx.doi.org/10.1111/apa.15522

Ejemplares similares